Jam City and Disney Announce Multi-Year Mobile Games Development Partnership
Jam City, a leader in mobile entertainment, today announced a multi-year mobile games development partnership with Disney that includes Jam City taking over Disney’s popular mobile game, Disney Emoji Blitz. Members of Disney’s Glendale Games Studio will join Jam City and continue to operate and grow Disney Emoji Blitz as part of the Jam City team. Jam City will also have the right to develop new mobile games based on iconic characters and stories from Pixar and Walt Disney Animation Studios. The first game Jam City and Disney plan to develop is a mobile game based on Disney Animation’s Frozen sequel.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005011/en/
Jam City and Disney Announce Multi-Year Mobile Games Development Partnership (Graphic: Business Wire)
“Jam City is proud to be teaming with Disney,” said Chris DeWolfe, co-founder and CEO of Jam City. “Disney is the world’s leader in beloved characters and brands that have engaged generations of fans for decades. Jam City’s leadership in mobile entertainment based on iconic entertainment IP, makes our company an ideal partner to develop a lineup of new mobile games with Disney’s most popular franchises.”
“While our licensing business for Disney Animation and Pixar games has grown over the last year and we have several top developers creating Disney games, this deal with Jam City represents a significant long-term opportunity for our games business and for the future slate of Disney and Pixar games,” said Kyle Laughlin, Senior Vice President of Games and Interactive Experiences at Disney. “We can’t wait to see how Jam City and the incredibly talented team behind Disney Emoji Blitz will grow the already successful game and franchise, and how Jam City will bring their global reach and expertise in developing successful, enduring mobile games to the upcoming titles.”
Through Disney Emoji Blitz, players collect and match hundreds of Disney Animation, Pixar and Star Wars emojis. The game’s players also earn prizes, complete missions, and discover new emoji characters from Disney Animation’s Wreck-It Ralph, Mickey Mouse & Friends, Disney Villains, Pixar's Toy Story and more. Disney Emoji Blitz engages users by combining a unique match-3 blitz game with a deep emoji collection mechanic.
Disney Emoji Blitz is currently available on the App Store and Google Play. Other free-to-play mobile titles developed under the Jam City and Disney agreement will be available worldwide on the App Store and Google Play.
About Jam City
Jam City is a leader in mobile entertainment, providing unique and deeply engaging games that appeal to broad global audiences. Jam City was founded in 2009 by MySpace co-founder and CEO Chris DeWolfe and former 20th Century Fox executive Josh Yguado. Jam City is the creative powerhouse behind some of the highest grossing and most enduring social gaming franchises for mobile, including Cookie Jam (Facebook “Game of the Year” winner) and Panda Pop. Jam City is the go-to studio for Hollywood, having developed immersive, narrative rich mobile games around iconic entertainment brands including Harry Potter, Family Guy and Marvel Avengers. Jam City has studios in Los Angeles (HQ), San Francisco, San Diego, Bogotá and Buenos Aires. The Jam City team is known for its creative excellence and technological innovation in key areas including storytelling, data science and audience insights.
About Disney Parks, Experiences and Consumer Products
Disney Parks, Experiences and Consumer Products is the business segment of The Walt Disney Company (NYSE:DIS) that brings the magic of Disney's stories, characters and franchises into the daily lives of families and fans around the world to create memories that last a lifetime. The company's iconic travel and leisure businesses include six resort destinations in the United States, Europe, and Asia; a top-rated cruise line; a luxurious family beach resort in Hawaii; a popular vacation ownership program; and an award-winning guided family adventure business. Disney's global consumer products operations include the world's leading licensing business; the world's largest children's print publisher; Disney Store locations around the world; and the shop Disney e-commerce platform. These experiences are created by Walt Disney Imagineering, the innovative force responsible for overseeing the segment's world-class products and experiences — from immersive lands to interactive toys, and everything in between.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181114005011/en/
Contact information
Jam City
Sarah Ross, 310-924-1404
sarahr@jamcity.com
or
Disney
Amanda
Gonzalez, 415-623-1159
amanda.gonzalez@disney.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom